MONTREAL, Oct. 1, 2024 /CNW/ - Valeo Pharma Inc. (VPH:CA) (TSX: VPH) (FSE: VP2), a Canadian pharmaceutical company, announced today that the Québec Superior Court (Commercial Division) (the "Court") ...

MONTREAL, Aug. 29, 2024 /CNW/ - Valeo Pharma Inc (VPH:CA). (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that the Company is ...

Looking for the most shorted stocks?

In a report released today, Stefan Quenneville from Echelon Wealth Partners reiterated a Buy rating on Valeo Pharma (VPHIF – Research Report), with a price target of C$0.50. Stefan Quenneville’s ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on 4D Molecular Therapeutics (FDMT – Research Report), Valeo Pharma (VPHIF – Research Report) and AbbVie ...

Valeo Pharma (TSE:VPH) has released an update. Valeo Pharma has reported a record increase in Q2-2024 revenues, reaching $14.1 million, a 4% rise from the previous year, despite a higher adjusted ...

MONTREAL, Feb. 6, 2025 /CNW/ - Valeo Pharma Inc. ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it has closed a share purchase agreement (the "Transaction") with ...

Forward-looking statements are statements and information regarding possible events, conditions or results of operations that are based upon assumptions about future economic conditions and courses of ...

Valeo Pharma Inc. company facts, information and financial ratios from MarketWatch.

The table below includes insider transactions amounts, trade dates and executives completing transactions. Valeo Pharma insider trades include the CEO, CFO, board of directors and is updated today.

This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an ...

- Valeo Pharma and Zambon previously announced a partnership which grants Valeo Pharma exclusive Canadian rights to commercialize safinamide (known as Onstryv® in Canada and Xadago® in the rest of the ...